NEW YORK, March 21, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Bristol-Myers Squibb Company (NYSE: BMY), Galena Biopharma, Inc.
(NASDAQ: GALE), Teleflex Incorporated (NYSE: TFX), GW
Pharmaceuticals plc (NASDAQ: GWPH), and CytRx Corporation (NASDAQ:
CYTR). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
Bristol-Myers Squibb Company Analyst Notes
On March 14, 2014, Bristol-Myers
Squibb Company (Bristol-Myers Squibb) announced that the U.S. Food
and Drug Administration (FDA) approved a Supplemental New Drug
Application (sNDA) for Eliquis (apixaban) in patients who have
undergone hip or knee replacement surgery. This sNDA approval for
Eliquis for the prophylaxis of deep vein thrombosis (DVT) is
supported by three clinical trials. "Today's FDA approval of
Eliquis for DVT prophylaxis in patients who have undergone hip or
knee replacement is a significant milestone for this important
medicine, which is also approved to reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial
fibrillation," said Brian Daniels,
M.D., Senior Vice President of Global Development and Medical
Affairs at Bristol-Myers Squibb. The full analyst notes on
Bristol-Myers Squibb Company are available to download free of
charge at:
http://www.AnalystsReview.com/03212014/BMY/report.pdf
Galena Biopharma, Inc. Analyst Notes
On March 17, 2014, Galena
Biopharma, Inc. (Galena) reported its Q4 2013 and full-year 2013
financial results. For Q4 2013, the Company reported net revenue of
$1.3 million, whereas no revenues
were recognized in the comparable previous year period. Net loss
for the quarter was $48.5 million, or
$0.46 per diluted share, compared to
a net loss of $3.2 million, or
$0.05 per diluted share, in Q4 2012.
For full-year 2013, net revenue was $2.5
million, whereas no revenues were recognized for the
comparable previous year period. Full-year net loss was
$76.7 million or $0.85 per diluted share, compared to a net loss
of $35.0 million or $0.56 per diluted share in 2012. Ryan Dunlap, Vice President and CFO of Galena
said, "We are pleased to report $2.5
million net revenue for Abstral consistent with our guidance
of $1.5 to $3 million for 2013. We
expect net revenue to increase throughout 2014 based on anticipated
increases in the number of Abstral prescriptions fulfilled,
combined with the execution of programs which are projected to
significantly reduce our gross-to-net revenue adjustments." The
full analyst notes on Galena Biopharma, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/03212014/GALE/report.pdf
Teleflex Incorporated Analyst Notes
On March 17, 2014, Teleflex
Incorporated (Teleflex) announced FDA 510(k) clearance for restated
Indications for Use of the EZ-IO® Vascular Access System. The
EZ-IO® 25 mm Needle Set is now indicated for patients 3 kg or over.
"As part of our fight for zero complications in vascular access, we
are committed to continuously improving our technologies, enhancing
our training and educational initiatives, and partnering with
healthcare professionals to provide innovative solutions for
treating difficult vascular access patients with the EZ-IO®
Vascular Access System," said Jay
White, President and General Manager of Vascular Access
Division at Teleflex. The full analyst notes on Teleflex
Incorporated are available to download free of charge at:
http://www.AnalystsReview.com/03212014/TFX/report.pdf
GW Pharmaceuticals plc Analyst Notes
On March 17, 2014, GW
Pharmaceuticals plc (GW Pharmaceuticals) announced updates on the
Company's cannabinoid pipeline. The Company has completed a Phase 1
clinical trial of GWP42006 to treat epilepsy. GWP42006 is a product
which features the non-psychoactive cannabinoid cannabidivarin
(CBDV) extracted from the cannabis plant. CBDV has shown the
ability to treat seizures in pre-clinical models of epilepsy with
significantly fewer side effects than currently approved
anti-epileptic drugs. The Company also commenced a 12-week
randomized, double blind, placebo controlled Phase 2b study of
GWP42004 to treat Type 2 diabetes. GW believes that GWP42004 would
have the potential to offer a novel orally-administered treatment
option within one of the largest therapeutic areas where a serious
unmet medical need still exists. GW has also commenced a Phase 2a
trial using GWP42003 to treat Schizophrenia. GWP42003 has shown
notable anti-psychotic effects in accepted pre-clinical models of
schizophrenia and has also demonstrated the ability to reduce the
characteristic movement disorders induced by currently available
anti-psychotic agents. The full analyst notes on GW Pharmaceuticals
plc are available to download free of charge at:
http://www.AnalystsReview.com/03212014/GWPH/report.pdf
CytRx Corporation Analyst Notes
On March 5, 2014, CytRx Corp.
(CytRx) reported its full-year 2013 financial results. The Company
reported net loss of $47.5 million,
or $1.44 per diluted share, compared
with a net loss of $18.0 million, or
$0.78 per diluted share in full year
2012. Steven A. Kriegsman, CytRx
President and CEO, said, "We are entering 2014 on firm financial
ground, having recently raised approximately $86 million, before deducting expenses, along
with a cash balance of $38.5 million
at year end 2013. With this strong balance sheet, we are well
funded to execute on our corporate objectives for the foreseeable
future." In October 2013 and
February 2014, CytRx successfully
completed two public offerings of common stock securing gross
proceeds of approximately $26 million
and $86 million, respectively. The
full analyst notes on CytRx Corporation are available to download
free of charge at:
http://www.AnalystsReview.com/03212014/CYTR/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
-
For any urgent concerns or inquiries,
please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review